This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Matria Moves from Buyer to Seller

OKLAHOMA CITY -- Weakened by a huge acquisition -- and still searching for a miracle cure -- Matria (MATR - Get Report) has decided to put itself up for sale.

The Georgia-based disease-management outfit said Tuesday that it is pursuing strategic initiatives that could lead to a possible buyout of the company. While Matria said that it has reached an "advanced stage" in its efforts, the company stopped short of guaranteeing a sale.

The company has suspended plans to give 2008 guidance, originally scheduled for release this Thursday, in the meantime.

Matria's stock -- which earlier in the day fell as much as 12% on an analyst downgrade -- soared 22% to $29.95 on the news. That move pushed the shares into the upper half of their 52-week trading range.

Just a year ago, Matria fully intended to find success on its own. Back then, Matria was the buyer -- having just acquired rival CorSolutions -- with big plans to dominate the booming disease-management space.

But that ambitious acquisition caused unexpected headaches, leading to painful contract losses and financial shortfalls. Indeed, virtually every quarter brought a new disappointment over the course of the past year.

Thus, even before this week's news, analysts had started to wonder if major changes -- including a management shakeup or outright sale -- could be on the way. In an ill-timed downgrade, issued just hours before Tuesday's announcement, Credit Suisse analyst Michael Glynn slapped an underperform rating on the stock.

Glynn, whose firm has investment banking ties to Matria, believes that the company has a possible revenue shortfall looming, and may see its stock come under pressure as a result. Glynn, for one, felt uncomfortable relying on the buyout prospects that seemed to be boosting the company's shares.

"In late December, amidst a lack of news, take-out speculation emerged that suggested Matria would be a good strategic fit with a pharmacy or a supermarket with pharmacy operations," he wrote. "Strategically, it makes some sense ... However, we have no reason to believe [merger and acquisition] activity is closer than it has been in the past."

Meanwhile, in a reversal of past trends, a bullish call on Matria actually paid off. As Glynn threw in the towel, Broadpoint Capital analyst Glenn Garmont stuck with Matria in hopes of a takeover.

"Matria has struggled with its financial forecasts since the CorSolutions acquisition, reflecting the lumpier nature of larger health plan contracts versus Matria's legacy employer business," Glenn acknowledged on Tuesday. "However, we are maintaining our buy rating, as we believe Matria's current valuation likely already discounts this risk."

Moreover, he added, "our positive rating is further buoyed by recent private-company M&A in the sector that ... implies a higher valuation for Matria."

Garmont values Matria at $30 a share, a target that now looks achievable if the company in fact manages to land a deal. Still, the same stock fetched far more -- peaking above $40 a share less than a year ago -- when Matria was still promising explosive growth as standalone company.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MATR $3.92 -0.76%
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs